MX2021014157A - Formas cristalinas de un inhibidor btk. - Google Patents
Formas cristalinas de un inhibidor btk.Info
- Publication number
- MX2021014157A MX2021014157A MX2021014157A MX2021014157A MX2021014157A MX 2021014157 A MX2021014157 A MX 2021014157A MX 2021014157 A MX2021014157 A MX 2021014157A MX 2021014157 A MX2021014157 A MX 2021014157A MX 2021014157 A MX2021014157 A MX 2021014157A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- disorders
- btk inhibitor
- diseases
- btk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente solicitud se refiere a varias formas cristalinas anhidras N-(3-(6-amino-5-(2-(N-metilacrilamido)etoxi)pirimidin-4-i l)-5-fluoro-2-metilfenil)-4-ciclopropil-2-fluorobenzamida, así como composiciones, método de fabricación y sus métodos de uso. Estas formas cristalinas son útiles en el tratamiento de enfermedades y trastornos que típicamente se mejoran mediante la inhibición de BTK. Dichas enfermedades y trastornos pueden incluir trastornos inflamatorios y autoinmunes e inflamación pulmonar y del tracto respiratorio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962851986P | 2019-05-23 | 2019-05-23 | |
PCT/IB2020/054752 WO2020234779A1 (en) | 2019-05-23 | 2020-05-20 | Crystalline forms of a btk inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014157A true MX2021014157A (es) | 2022-01-04 |
Family
ID=70918748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014157A MX2021014157A (es) | 2019-05-23 | 2020-05-20 | Formas cristalinas de un inhibidor btk. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3972960A1 (es) |
JP (1) | JP2022534216A (es) |
KR (1) | KR20220012280A (es) |
CN (1) | CN113840821A (es) |
AR (1) | AR118981A1 (es) |
AU (1) | AU2020279927A1 (es) |
BR (1) | BR112021023054A2 (es) |
CA (1) | CA3137790A1 (es) |
CL (1) | CL2021003057A1 (es) |
IL (1) | IL287668A (es) |
MX (1) | MX2021014157A (es) |
TW (1) | TW202110811A (es) |
WO (1) | WO2020234779A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022033569A1 (zh) * | 2020-08-14 | 2022-02-17 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物的晶型及其制备方法 |
TW202245778A (zh) | 2021-01-26 | 2022-12-01 | 瑞士商諾華公司 | 藥物組成物 |
IL310975A (en) | 2021-09-03 | 2024-04-01 | Novartis Ag | LOU064 for the treatment of multiple sclerosis |
JP2024504267A (ja) | 2021-12-14 | 2024-01-31 | ノバルティス アーゲー | Lou064を使用した治療の方法 |
TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用lou064治療化膿性汗腺炎之方法 |
WO2024069507A1 (en) | 2022-09-30 | 2024-04-04 | Novartis Ag | Synthesis methods and intermediates for the production of remibrutinib |
CN117024354B (zh) * | 2023-10-08 | 2023-12-08 | 天津凯莱英制药有限公司 | 瑞米布替尼的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020544A1 (es) | 2000-11-07 | 2002-07-30 | Novartis Ag | Derivados de indolilmaleimida |
TW200918046A (en) | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
BR0317099A (pt) | 2002-12-09 | 2005-10-25 | Boardd Of Regents Of The Unive | Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica |
AU2004251146A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
ZA200602666B (en) | 2004-01-12 | 2007-09-26 | Cytopia Res Pty Ltd | Selective kinase inhibitors |
US9512084B2 (en) * | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
-
2020
- 2020-05-20 MX MX2021014157A patent/MX2021014157A/es unknown
- 2020-05-20 KR KR1020217041087A patent/KR20220012280A/ko unknown
- 2020-05-20 CA CA3137790A patent/CA3137790A1/en active Pending
- 2020-05-20 AU AU2020279927A patent/AU2020279927A1/en active Pending
- 2020-05-20 JP JP2021569267A patent/JP2022534216A/ja active Pending
- 2020-05-20 BR BR112021023054A patent/BR112021023054A2/pt unknown
- 2020-05-20 WO PCT/IB2020/054752 patent/WO2020234779A1/en unknown
- 2020-05-20 EP EP20729201.2A patent/EP3972960A1/en active Pending
- 2020-05-20 CN CN202080036320.6A patent/CN113840821A/zh active Pending
- 2020-05-21 AR ARP200101442A patent/AR118981A1/es unknown
- 2020-05-21 TW TW109116921A patent/TW202110811A/zh unknown
-
2021
- 2021-10-28 IL IL287668A patent/IL287668A/en unknown
- 2021-11-19 CL CL2021003057A patent/CL2021003057A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3972960A1 (en) | 2022-03-30 |
KR20220012280A (ko) | 2022-02-03 |
IL287668A (en) | 2021-12-01 |
CA3137790A1 (en) | 2020-11-26 |
AU2020279927A1 (en) | 2022-01-06 |
CL2021003057A1 (es) | 2022-09-09 |
JP2022534216A (ja) | 2022-07-28 |
CN113840821A (zh) | 2021-12-24 |
AR118981A1 (es) | 2021-11-17 |
WO2020234779A1 (en) | 2020-11-26 |
BR112021023054A2 (pt) | 2022-03-29 |
TW202110811A (zh) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014157A (es) | Formas cristalinas de un inhibidor btk. | |
GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
EA202090256A1 (ru) | 5-членные и бициклические гетероциклические амиды в качестве ингибиторов rock | |
TN2019000281A1 (en) | Ferroportin-inhibitor salts | |
WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
EA201070328A1 (ru) | Соединения триазолопиридина и их применение в качестве ингибиторов ask | |
IN2014DN09352A (es) | ||
IN2014DN09348A (es) | ||
NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
EA201001821A1 (ru) | Производные триазола, полезные для лечения заболеваний | |
MX2010007683A (es) | Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met. | |
MX367154B (es) | Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico. | |
EA201270716A1 (ru) | Макроциклы в качестве ингибиторов фактора xia | |
CU20200084A7 (es) | Derivados sustituidos de la carboxamida dihidropirazolo pirazina | |
CR20200413A (es) | Inhibidores de canal de potencial de receptor transitorio de oxadiazol | |
EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
CR20210072A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
MX2018001204A (es) | Metodo para preparar derivados de acido 3-(2-anilino-1-ciclohexil- 1h-bencimidazol-5-il)propanoico sustituido. | |
MX2021009521A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
NZ738836A (en) | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
IN2014DN09347A (es) | ||
EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 |